Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUTRENEO: Durvalumab and Tremelimumab in Neoadjuvant Bladder Cancer
NCT03472274Phase 2Completed
- Sponsor
- Fundación CRIS contra el Cáncer
- Start
- Oct 2018
- Primary completion
- Apr 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in muscle-invasive bladder cancer (MIBC), sponsored by Fundación CRIS contra el Cáncer. Started Oct 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03472274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472274.